title: The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab.
authors.forename: Charles
authors.initials: C
authors.lastname: Alderman
authors.forename: Jonathan
authors.initials: J
authors.lastname: Corlett
authors.forename: Jonathan
authors.initials: J
authors.lastname: Cullis
mesh_terms: D000281:Administration, Intranasal; D000336:Aerosols; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D002425:Cautery; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D004844:Epistaxis / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D005260:Female; D006801:Humans; D054025:Lasers, Dye / Q000627:therapeutic use; D008297:Male; D009297:Nasal Mucosa / Q000187:drug effects; D012008:Recurrence; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000150:complications*
chemical_list: D000336:Aerosols; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
keywords: anaemia; antibody therapy; bleeding disorders; vascular endothelial growth factor